Evidence map›Paper›PMID 22177802›Full record

ArticleMolecular oncology2012

uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.

Hari Raghu, Arun Kumar Nalla, Christopher S Gondi, Meena Gujrati, Dzunh H Dinh, Jasti S Rao

Open access · bronzeAbstract read
In one paragraph

Article in Molecular oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Nanoparticulate RNA delivery systems in cancer.Cancer reports (Hoboken, N.J.) · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hari RaghuDepartment of Cancer Biology and Pharmacology, University of Illinois College of Medicine, Peoria, IL 61605, USA.
Arun Kumar Nalla
Christopher S Gondi
Meena Gujrati
Dzunh H Dinh
Jasti S Rao
University of Illinois Urbana-Champaign · USIllinois College · US

Funding

Role of uPA and uPAR in Human Glioma InvasivenessR01CA075557 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI RAO, JASTI S. · 1998 to 2009
$2.3M
NCI NIH HHS CA75557NCI NIH HHS R01 CA075557
6 · The paper itself

Abstract

The uPA/uPAR system is known to play a critical role in angiogenesis of glioblastoma. Previously, we have shown that shRNA against uPA and uPAR attenuates angiogenesis by blocking nuclear translocation of angiogenin, inhibition of angiopoietin/Tie2 signaling, and regulating several other pro-angiogenic, angiostatic and anti-angiogenic molecules. Further analysis revealed that GM-CSF, a pleiotropic cytokine, was significantly inhibited in U87MG and 4910 co-cultures with endothelial cells transfected with shRNA against uPA and uPAR. The role of the uPA/uPAR system in this process is not completely understood. Analysis of tumor conditioned medium of U87MG, 4910 and HMECs transfected with shRNA against uPA or uPAR alone or in combination (pU2) revealed inhibition of GM-CSF-enhanced secretion of SVEGFR1 as shown by Western blotting and ELISA. Moreover, phosphorylation of JAK2 and STAT5, the downstream effectors of GM-CSF signaling, was also inhibited in all three cell lines. Phosphorylation at Tyr 166 position of the GM-CSFRβ subunit, the signal activating subunit of the GM-CSF receptor, was inhibited in HMEC, U87MG and 4910 cells. Further analysis revealed that shRNA against uPA and/or uPAR increased secretion of TIMP-1, which is known to enhance SVEGFR1 secretion in endothelial cells. Moreover, addition of purified uPA (with and without GM-CSF) activated JAK2/STAT5 signaling in HMEC. Exogenous addition of SVEGFR1 to pU2 tumor conditioned medium enhanced inhibition of VEGF-induced endothelial capillary tube formation as assessed by an in vitro angiogenesis assay. To determine the significance of these events in vivo, nude mice with pre-established tumors treated with shRNA against uPA and/or uPAR showed decreased levels of GM-CSF and increased levels of SVEGFR1 and TIMP-1 when compared with controls. Enhanced secretion of SVEGFR1 by puPA, puPAR and pU2 in endothelial and GBM cells was mediated indirectly by MMP-7 and augmented by ectodomain shedding of VEGFr1 by tyrosine phosphorylation at the 1213 position. Taken together, these results suggest that the uPA/uPAR system could prove beneficial as an indirect target for inhibition of angiogenesis in glioblastoma.

Indexed as

Neovascularization, PhysiologicAnimalsBlotting, WesternCell Line, TumorEndothelial CellsEnzyme-Linked Immunosorbent AssayGlioblastomaGranulocyte-Macrophage Colony-Stimulating FactorHumansJanus Kinase 2Matrix Metalloproteinase 7MiceMicrovesselsModels, BiologicalPhosphorylationPhosphotyrosineGranulocyte-Macrophage Colony-Stimulating FactorJAK2 protein, humanJanus Kinase 2Matrix Metalloproteinase 7PhosphotyrosineReceptors, Granulocyte-Macrophage Colony-Stimulating FactorReceptors, Urokinase Plasminogen ActivatorRNA, Small InterferingSTAT5 Transcription FactorTissue Inhibitor of Metalloproteinase-1Urokinase-Type Plasminogen ActivatorVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID22177802
PMCPMC3268919
OpenAlexW2012532921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.